Supplementary Material (ESI) for Lab on Chip This journal is © The Royal Society of Chemistry 2011 Supporting Information Nanosized drug formulations under microfluidic continuous flow Selvi Dev a , K. Swaminathan Iyer* a and Colin L. Raston* a Centre for Strategic Nano-Fabrication, School of Biomedical, Biomolecular and Chemical Sciences. The University of Western Australia, Crawley, WA 6009, Australia. Materials and Methods: Meloxicam,4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carbox- amide-1,1-dioxide (Fig.1) is a nonsteroidal anti-inflammatory drug (NSAID). Meloxicam BP was purchased from Dayang Chemical, Hangzhou, China, and was used as received. Poloxamer 188 was purchased from BASF, Germany, and used as received. A micro fluidic continuous flow rotating tube processor has been used to prepare the drug nanopartciles. A set flow of liquids were introduced from a conical inlet at one end of the tube, with the discharged liquid collected by a peripheral ring at the other end. Three components were used, meloxicam, organic solvent (benzyl alcohol) and surfactants (Poloxamer 188). Integrated feed pumps were used to deliver the drug dissolved in a solvent, and antisolvent, with and without the addition of poloxamer (in water), with flow rates at 0.3 ml/s and 0.6 ml/s respectively. An organic phase (benzyl alcohol) containing meloxicam was emulsified at different stirring rate of 500 rpm- G force: 16.8 g, 1000 rpm- G force: 67.2 g and 1500 rpm-G force: 151.2 g, with the rotating tube operating at room temperature. Concentration of the drug 3mg/ml in benzyl alcohol was maintained throughout the experiments. Electronic Supplementary Material (ESI) for Lab on a Chip This journal is © The Royal Society of Chemistry 2011